Conjugate vaccines merge non-immunogenic antigens, such as bacterial polysaccharides or short peptides, with protein-carrier antigens, thereby triggering, intensifying, and prolonging the immunological response. Conjugate vaccines offer speed, affordability, and high effectiveness, presenting an appealing alternative to traditional vaccines.
With two decades of experience, Intravacc excels in the design, development, and characterization of conjugate vaccines. Our Hib vaccine, for example, has been saving lives in India for years. More recently, Intravacc contributed to a project producing a semi-synthetic conjugate vaccine targeting Shigella flexneri 2a.
We have well-established and effective methods to purify polysaccharides and enable conjugation. Using advanced techniques, including high-performance liquid chromatography (HPLC), mass spectrometry, nuclear magnetic resonance (NMR), and colorimetric assays, we also rigorously assess every production step. Beyond classical conjugation, we are pioneering polysaccharide and peptide conjugation to outer membrane vesicles and synthetic polymers.
You can send us an email:
info@intravacc.nl
Reach out to Business Development:
BD@intravacc.nl
Or pick up the phone:
+31 30 792 03 00
You can also just fill out the contact form on the right.
We look forward to hearing from you!
